Advantage Alpha Capital Partners LP Sells 14,715 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Advantage Alpha Capital Partners LP lowered its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 59.1% in the 4th quarter, HoldingsChannel reports. The fund owned 10,199 shares of the biopharmaceutical company’s stock after selling 14,715 shares during the period. Advantage Alpha Capital Partners LP’s holdings in ACADIA Pharmaceuticals were worth $187,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company’s stock valued at $255,939,000 after purchasing an additional 104,444 shares during the last quarter. State Street Corp raised its holdings in ACADIA Pharmaceuticals by 3.0% during the 3rd quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after buying an additional 173,084 shares during the period. Fred Alger Management LLC lifted its position in ACADIA Pharmaceuticals by 17.8% in the third quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company’s stock worth $49,007,000 after buying an additional 481,950 shares during the last quarter. Geode Capital Management LLC boosted its stake in ACADIA Pharmaceuticals by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock worth $44,234,000 after buying an additional 30,826 shares during the period. Finally, SG Americas Securities LLC increased its position in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ACAD shares. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 6,167 shares of company stock valued at $114,583. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ:ACAD opened at $17.23 on Tuesday. The firm has a 50 day moving average of $18.36 and a 200 day moving average of $17.02. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of 22.09 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.15 and a 52 week high of $20.68.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.